Vilazodone
| Clinical data | |
|---|---|
| Pronunciation | /vɪˈlæzədoʊn/ vi-LAZ-ə-dohn |
| Trade names | Viibryd |
| Other names | EMD-68843; SB-659746A |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611020 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Serotonin modulator[1] |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 72% (oral, with food)[5] |
| Metabolism | Liver via CYP3A4[5] |
| Elimination half-life | 25 hours[5] |
| Excretion | Faecal and renal[5] |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI |
|
| ChEMBL |
|
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H27N5O2 |
| Molar mass | 441.535 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder.[1] It is classified as a serotonin modulator[1] and is taken by mouth.[1]
Its common side effects include nausea, diarrhea, and trouble sleeping.[1] Serious side effects may include increased suicidal thoughts or actions in those under the age of 25, serotonin syndrome, bleeding, mania, pancreatitis, and syndrome of inappropriate antidiuretic hormone secretion (SIADH).[1] Vilazodone may cause less emotional blunting than typical selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs).[6] A withdrawal syndrome may occur if the dose is rapidly decreased.[1] Use during pregnancy and breastfeeding is not generally recommended.[7] It is in the serotonin modulator class of medications and is believed to work both as an SSRI and activator of the 5-HT1A receptor.[1]
Vilazodone was approved for medical use in the United States in 2011[1] and in Canada in 2018.[8] In 2019, it was the 334th most commonly prescribed medication in the United States, with more than 900 thousand prescriptions.[9] The drug lost patent protection in June 2022 for adults and in July 2023 for pediatrics.[10] Generic versions have been approved by the US Food and Drug Administration.[11][12]
- ^ a b c d e f g h i "Vilazodone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved March 3, 2019.
- ^ Anvisa (March 31, 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published April 4, 2023). Archived from the original on August 3, 2023. Retrieved August 16, 2023.
- ^ "Viibryd Product information". Health Canada. April 25, 2012. Retrieved June 10, 2022.
- ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. May 4, 2016. Retrieved April 7, 2024.
- ^ a b c d e "Viibryd (vilazodone hydrochloride) tablet Viibryd (vilazodone hydrochloride) kit [Forest Laboratories, Inc.]". DailyMed. Forest Laboratories, Inc. December 2012. Archived from the original on October 29, 2013. Retrieved October 28, 2013.
- ^ Hughes S, Lacasse J, Fuller RR, Spaulding-Givens J (September 2017). "Adverse effects and treatment satisfaction among online users of four antidepressants". Psychiatry Research. 255: 78–86. doi:10.1016/j.psychres.2017.05.021. PMID 28531820. S2CID 4572360.
- ^ "Vilazodone (Viibryd) Use During Pregnancy". Drugs.com. Retrieved March 21, 2019.
- ^ "Drug Product Database Online Query". Health Canada. Government of Canada. April 25, 2012. Retrieved May 18, 2020.
- ^ "Vilazodone - Drug Usage Statistics". ClinCalc. Archived from the original on July 8, 2020. Retrieved October 16, 2021.
- ^ "Generic Viibryd Availability".
- ^ "Vilazodone: FDA-Approved Drugs". Archived from the original on May 1, 2017.
- ^ "2019 First Generic Drugs Approvals". U.S. Food and Drug Administration (FDA). January 21, 2021. Archived from the original on August 5, 2020. Retrieved June 10, 2022.